US delay for Roche's Actemra as FDA needs more info
This article was originally published in Scrip
Executive Summary
Roche/Chugai's novel rheumatoid arthritis drug Actemra (tocilizumab) is the subject of a complete response letter from the USFDA, Roche revealed on September 18th, the drug's user fee date.